MS Fatigue Post High‐Efficacy Treatment
European Journal of Neurology · 2025
DOI: 10.1111/ene.70385 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Neurology, 2025. Verfasst von C Sales und 4 weiteren Autor:innen. Beteiligte Einrichtung: ANU College of Law, Governance and Policy, Australian National University, Canberra, Australia. Hauptthemen laut MEDLINE: Fatigue, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Multiple sclerosis (MS) is a major cause of disability, particularly among young adults, with fatigue affecting up to 95% of patients. Despite the availability of disease‐modifying therapies (DMTs), their impact on MS‐related fatigue (MSF) remains uncertain. This study investigates changes in fatigue levels among individuals with relapsing–remitting MS (RRMS) following the initiation of highly effective therapies (HETs).
Methods
A systematic search of MEDLINE, PubMed, Scopus, and PsycINFO identified studies involving adults with RRMS treated with HETs and assessed using validated fatigue measures at baseline and follow‐up. Data on demographics, MS duration, DMT type, and fatigue scores were extracted. Meta‐analyses using a random‐effects model calculated standardized mean differences (SMD) in fatigue scores post‐treatment.
Results
Eighteen studies comprising 4138 RRMS patients and 3806 person‐years of follow‐up were included. The overall SMD was −0.34 (95% CI −0.47 to −0.21), indicating a small but significant reduction in fatigue. Continuous treatments (e.g., natalizumab, ocrelizumab, fingolimod) showed significant improvements, while immune reconstituting therapies (e.g., alemtuzumab) did not. Among fatigue domains, only physical fatigue showed a significant reduction, particularly with natalizumab (SMD = −1.25; 95% CI −2.43 to −0.06) and when assessed using the fatigue scale for motor and cognitive functions scale (SMD = −1.52; 95% CI −2.87 to −0.17).
Conclusion
MS‐related fatigue levels, especially in its physical aspect, decrease after the initiation of HET. This finding reinforced the role of neuroinflammation in driving fatigue and highlighted the need for domain‐specific research and treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ANU College of Law, Governance and Policy, Australian National University, Canberra, Australia.
- Department of Neurology, The North Canberra Hospital, Canberra, Australia.
- Department of Neurology & Stroke Services, Western Health, Melbourne, Australia.
- John Curtin School of Medical Research, Australian National University, Canberra, Australia.
ORCID-Profile: C Sales, T Wijeratne, A Bruestle, N Cherbuin
Zitieren
APA
Sales, C., Patel, R., Wijeratne, T., Bruestle, A., & Cherbuin, N. (2025). MS Fatigue Post High‐Efficacy Treatment. European Journal of Neurology. https://doi.org/10.1111/ene.70385
Vancouver
Sales C, Patel R, Wijeratne T, Bruestle A, Cherbuin N. MS Fatigue Post High‐Efficacy Treatment. European Journal of Neurology. 2025. doi:10.1111/ene.70385
BibTeX
@article{Sales2025,
author = {Sales, C and Patel, R and Wijeratne, T and Bruestle, A and Cherbuin, N},
title = {MS Fatigue Post High‐Efficacy Treatment},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70385}
}
EUVIMED